Cell death modulation via antagonists of Fasl and Fas activation
AssigneeUniversity of Pittsburgh—Of the Commonwealth System of Higher Education
InventorsAbdolreza Zarnegar, Marie DeFrances, Chun-Bin Zou
Life of this patent
Estimating the term…
Abstract
The invention provides a polypeptide that attenuates the activation of Fas, TNFR1, or both. The polypeptide can be used to treat conditions associated with dysregulation of the cell death or inflammatory pathway and can be formulated into pharmaceutical compositions for medical or veterinary use.
Claims35
A synthetic polypeptide that attenuates the activation of Fas or TNFR1 or both Fas and TNFR1, which consists of between about 4 and about 50 amino acids.
A synthetic polypeptide comprising between about 4 and about 50 amino acids, which comprises 4 contiguous amino acid residues having the sequence YLGA (SEQ ID NO:1), YLGG (SEQ ID NO:2), or FLGA (SEQ ID NO:
- 32).
A polypeptide consisting essentially of a C-terminal truncation of the alpha subunit of the Met receptor that attenuates the activation of Fas, TNFR1 or both Fas and TNFR1.
The method of claim 18, wherein said cell death is apoptosis.
Dependencies are inferred from the claim text.